ES2240971T3 - Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas. - Google Patents

Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.

Info

Publication number
ES2240971T3
ES2240971T3 ES95900994T ES95900994T ES2240971T3 ES 2240971 T3 ES2240971 T3 ES 2240971T3 ES 95900994 T ES95900994 T ES 95900994T ES 95900994 T ES95900994 T ES 95900994T ES 2240971 T3 ES2240971 T3 ES 2240971T3
Authority
ES
Spain
Prior art keywords
genes
cell death
cytokine
expression
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900994T
Other languages
English (en)
Inventor
Adi Kimchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2240971T3 publication Critical patent/ES2240971T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23005—Cathepsin D (3.4.23.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

LA PRESENTE INVENCION SE BASA EN EL NUEVO DESCUBRIMIENTO DE QUE LA INHIBICION DE LA EXPRESION DE CIERTOS GENES CONTRARRESTA LA MUERTE DE CELULAS INDUCIDA POR LA CITOQUINA. MIENTRAS ESTOS GENES FUNCIONAN NORMALMENTE, LA CITOQUINA INDUCE LA MUERTE DE CELULAS; UNA VEZ INHIBIDA LA EXPRESION DE DICHOS GENES, SE INHIBE LA MUERTE DE CELULAS INDUCIDA POR LA CITOQUINA. DE ELLO SE DEDUCE QUE LA EXPRESION NORMAL ES LA MUERTE DE CELULAS INDUCIDA POR LA CITOQUINA. EN LAS CELULAS HELA, EL IFN-Y INDUCE UN PROCESO BIFASICO, QUE COMPRENDE UNA FASE CITOSTATICA INICIAL Y UNA FASE CITOTOXICA SUBSIGUIENTE (MUERTE DE CELULAS PROGRAMADA). SE HA DESCUBIERTO QUE LOS NUEVOS GENES DESCUBIERTOS DE LA PRESENTE INVENCION SOLO AFECTAN A LA ULTIMA, A LA FASE CITOTOXICA. ESTOS GENES, DENOMINADOS GENES "DAP" (PROTEINA ASOCIADA A LA MUERTE), INCLUYEN MOLECULAS DE ADN QUE CONTIENEN UNA SECUENCIA DE CODIFICACION QUE CODIFICA LOS PRODUCTOS DE EXPRESION DE LOS GENES DAP O LOS PRODUCTOS DE EXPRESION QUE TIENEN UNA ACTIVIDAD BIOLOGICA SIMILAR, Y A VECES SE LES DENOMINA DE FORMA COLECTIVA "MOLECULAS DE ADN DE ADP". A LOS PRODUCTOS DE EXPRESION DE LAS MOLECULAS DE ADN DE DAP A VECES SE LES DENOMINARA AQUI DENTRO DE FORMA COLECTIVA "PRODUCTOS DAP".
ES95900994T 1993-10-12 1994-10-12 Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas. Expired - Lifetime ES2240971T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10725093A IL107250A (en) 1993-10-12 1993-10-12 Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins

Publications (1)

Publication Number Publication Date
ES2240971T3 true ES2240971T3 (es) 2005-10-16

Family

ID=11065332

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900994T Expired - Lifetime ES2240971T3 (es) 1993-10-12 1994-10-12 Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.

Country Status (8)

Country Link
EP (2) EP1586642A2 (es)
JP (1) JP3791927B2 (es)
AT (1) ATE291619T1 (es)
CA (1) CA2174136A1 (es)
DE (1) DE69434315T2 (es)
ES (1) ES2240971T3 (es)
IL (1) IL107250A (es)
WO (1) WO1995010630A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160106A (en) * 1993-10-12 2000-12-12 Yeda Research & Development Co., Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
WO1998005777A2 (en) * 1996-08-02 1998-02-12 Dana-Farber Cancer Institute BCL-xη, A NOVEL BCL-x ISOFORM, AND USES RELATED THERETO
US5776759A (en) * 1996-09-26 1998-07-07 Incyte Pharmaceuticals, Inc. Two novel human cathepsin proteins
AU734220B2 (en) * 1996-11-20 2001-06-07 Oklahoma Medical Research Foundation Cloning and characterization of napsin, an aspartic protease
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6537784B1 (en) 1998-02-27 2003-03-25 Boehringer Ingelheim Pharmaceuticals Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
EP1064392A2 (en) * 1998-03-16 2001-01-03 Introgen Therapeutics, Inc. Multigene vectors
US7026148B1 (en) 1998-06-15 2006-04-11 Yeda Research And Development Co., Ltd. DAP-kinase related protein
AU4440899A (en) * 1998-06-15 2000-01-05 Yeda Research And Development Co. Ltd. Dap-kinase related protein
WO2000005419A1 (en) * 1998-07-24 2000-02-03 Yeda Research And Development Company Ltd. Prevention of metastasis with 5-aza-2'-deoxycytidine
WO2001026678A1 (en) * 1999-10-13 2001-04-19 Yeda Research And Development Co. Ltd. Short segments of dap-kinase
US6965023B2 (en) 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
WO2002040680A2 (en) * 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
AU2003227255A1 (en) * 2002-03-29 2003-10-13 Mitsubishi Pharma Corporation Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby
EP2545170A1 (en) 2010-03-11 2013-01-16 Yeda Research And Development Co. Ltd. Death associated protein 1 variants and use thereof for modulating autophagy
US9149523B2 (en) 2010-12-15 2015-10-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer and neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542096A (en) * 1983-02-25 1985-09-17 President And Fellows Of Harvard College Detecting rearranged human c-myc DNA fragments associated with oncogenes
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Also Published As

Publication number Publication date
DE69434315T2 (de) 2006-03-30
WO1995010630A1 (en) 1995-04-20
JPH09505992A (ja) 1997-06-17
EP0804613B1 (en) 2005-03-23
EP0804613A1 (en) 1997-11-05
DE69434315D1 (de) 2005-04-28
JP3791927B2 (ja) 2006-06-28
IL107250A (en) 2001-08-08
ATE291619T1 (de) 2005-04-15
EP1586642A2 (en) 2005-10-19
IL107250A0 (en) 1994-01-25
CA2174136A1 (en) 1995-04-20
EP0804613A4 (en) 1999-07-14

Similar Documents

Publication Publication Date Title
ES2240971T3 (es) Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.
FI97809B (fi) Rekombinantti-DNA-molekyyli, joka koodaa kudosperäisen plasminogeenin aktivaattorin (TPA) analogia
BR8107293A (pt) Polipetidio anti-viral dna de duplo cordao veiculo de expressao plasmidico replicavel microorganismo transformado plasmidio processo de formacao do dito dna e do dito polipeptidio composicao farmaceutica e uso do dito polipeptidio
WO1995031559A3 (en) Methods of inducing gene expression by ionizing radiation
NZ504214A (en) Recombination cloning using nucleic acids having recombination sites
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
EP0653940A4 (en) GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE.
NO974812D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
DE3682891D1 (de) Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
DE69839489D1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
NZ234453A (en) Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
HU9300397D0 (en) Method for modifying tropism of micor-organisms to cells, tissues and host organisms recombinant micro-organisms obtained by this way and their application in human and veterinary medicine
IL145514A0 (en) Akt nucleic acids, polypeptides, and uses thereof
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
ATE131175T1 (de) Protein mit fibroblasten-wachstumsfaktor- rezeptoraktivität.
WO2000030590A3 (en) Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
Margaritella et al. Specificity of the photo-crosslinking reaction between poly (U) and protein S1 on the Escherichia coli ribosome
WO2001057186A3 (en) Methods and compositions for diagnosis and treatment of cancer based on esf
Harary et al. Relief of cytotoxicity and enhancement of interferon inducer activity of double-stranded RNA by eukaryotic initiation factor 2
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
ATE277186T1 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози